Sugi Predict

Sugi Predict / Compounds / SCHEMBL2397306

SCHEMBL2397306

SCHEMBL2397306

COC(=O)c1ccc(-c2cccn(CCN3CCNC(=O)C3)c2=O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 3/20 0.39
▸ FLT1 P17948 3/20 0.39
▸ FGFR3 P22607 3/20 0.39
▸ KDR P35968 3/20 0.39
▸ PDGFRB P09619 2/20 0.39
▸ PDGFRA P16234 2/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CD274 Q9NZQ7 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ ALDH1A2 O94788 1/20 0.37
▸ ALDH1A3 P47895 1/20 0.37
▸ SMN1; SMN2 Q16637 5/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ CHKA P35790 1/20 0.37
▸ OPRD1 P41143 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12263363 0.88 MEN1 (0.40) MEN1RAB9AKMT2ACD274SMN1; SMN2
SCHEMBL2398557 0.86 CHKA (0.40) ALDH1A1ALDH1A2ALDH1A3SMN1; SMN2CYP1A2
SCHEMBL12263343 0.84 SMN1; SMN2 (0.52) MEN1KMT2AALDH1A1ALDH1A2ALDH1A3
SCHEMBL12263448 0.83 CHKA (0.51) ALDH1A1ALDH1A2ALDH1A3SMN1; SMN2CYP1A2
SCHEMBL12263346 0.83 SMN1; SMN2 (0.53) MEN1RAB9AKMT2AALDH1A1ALDH1A2
SCHEMBL12263291 0.82 SMN1; SMN2 (0.54) MEN1KMT2ACD274ALDH1A1SMN1; SMN2
SCHEMBL12263366 0.81 OPRK1 (0.45) ALDH1A1ALDH1A2ALDH1A3SMN1; SMN2CYP1A2
SCHEMBL12263308 0.81 ALDH1A1 (0.47) ALDH1A1ALDH1A2ALDH1A3SMN1; SMN2CYP1A2
SCHEMBL12263300 0.80 CARM1 (0.43) ALDH1A1ALDH1A2ALDH1A3SMN1; SMN2CYP1A2
SCHEMBL2396743 0.79 ALDH1A1 (0.46) MEN1KMT2AALDH1A1ALDH1A2ALDH1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022208-B2 Benzene derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2011-09-20 — — US disclosed
US-8022208-B2 Benzene derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2011-09-20 — — US disclosed
US-8022208-B2 Benzene derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2011-09-20 — — US disclosed
US-20090054352-A1 BENZENE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-02-26 — — US disclosed
US-20090054352-A1 BENZENE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-02-26 — — US disclosed
US-20090054352-A1 BENZENE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-02-26 — — US disclosed
EP-1947086-A1 BENZENE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2008-07-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054352-A1 BENZENE DERIVATIVE OR SALT THEREOF F12, F2, SERPINC1 FGFR1 1365/4885FLT1 1369/4885FGFR3 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.